| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $19.8M | — | +26.7% |
| SG&A Expense | $4.5M | — | +8.5% |
| Operating Income | -$24.3M | — | -22.9% |
| Net Income | -$23.0M | — | -35.3% |
| EPS (Basic) | -$1.23 | — | +11.5% |
| EPS (Diluted) | -$1.23 | — | +11.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $25.7M | -9.9% | +35.8% |
| Short-term Investments | $112.6M | -16.5% | -1.2% |
| Current Assets | $143.6M | -14.0% | +4.5% |
| Total Assets | $144.5M | -14.1% | +3.3% |
| Current Liabilities | $18.1M | -12.3% | +56.1% |
| Total Liabilities | $18.1M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$25.6M | — | -55.7% |
| Capital Expenditures | $6K | — | — |
| Investing Cash Flow | $22.5M | — | +23.9% |
| Free Cash Flow | -$25.6M | — | -55.8% |
| +41.4% |
| Stockholders' Equity | $126.3M | -14.3% | -0.6% |